Log in or Sign up for Free to view tailored content for your specialty!
Bone and Mineral Metabolism Disorders News
Use of SGLT2 inhibitors may not increase fracture risk in patients with CKD
While SGLT2 inhibitors are often associated with bone and mineral metabolism irregularities, it remains unclear if these are linked to higher fracture risk in patients with chronic kidney disease, according to recently published research.
Plant-based protein may preserve kidney function, but more research needed
Plant-based protein may preserve kidney function and help manage chronic kidney disease in certain patients, but current research remains limited to inform clinical direction, according to published data.
Log in or Sign up for Free to view tailored content for your specialty!
VIDEO: Correlations identified between skeletal muscle mass index, urea reduction ratio
AUSTIN, Texas — In this video at the National Kidney Foundation Spring Clinical Meetings, Glenn W. Brietzke, MS, RD, LD, CNSC, discusses his award-winning poster presentation at the National Kidney Foundation Spring Clinical Meetings.
Trial results show gout therapy of pegloticase, methotrexate maintained eGFR vs. placebo
AUSTIN, Texas —Results from a poster presentation here showed that patients with uncontrolled gout treated with the combined therapy of pegloticase and methotrexate saw a reduction in gout symptoms as well as a stable eGFR.
FDA grants 510(k) clearance for ureteroscope system LithoVue
The FDA granted 510(k) clearance to Boston Scientific Corporation for its LithoVue Elite Single-Use Digital Flexible Ureteroscope System, according to a press release.
Serum phosphorus levels largely increased since 2013 in US compared with other countries
Compared with patients in European countries and Japan, patients using in-center hemodialysis in the United States showed a significant increase in serum phosphorous levels , according to data published in Kidney Medicine.
FDA agency grants appeal of complete response letter for Ardelyx’s phosphate control drug
Ardelyx Inc. has been granted an appeal to a complete response letter issued last year by the FDA regarding the company’s new drug application for its phosphate absorption inhibitor drug Xphozah.
Pill burden, adverse events signal new treatments needed for phosphorus management
Shivam Joshi, MD, knows he has few options for his patients on dialysis when it comes to the management of hyperphosphatemia. And none are very effective.
FDA investigates risk of hypocalcemia for patients on dialysis using Prolia
The FDA is investigating the risk of severe hypocalcemia in patients on dialysis treated with the osteoporosis drug Prolia, according to a drug safety communication.
Potassium monitoring device saves money, increases quality of life in patients on dialysis
ORLANDO — Using a real-time potassium monitoring device in patients on hemodialysis saves more money than the usual care and increases quality of life, according to a presenter at ASN Kidney Week.
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read